Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Lipitor Sees Big Boost From Medicare

This article was originally published in RPM Report

Executive Summary

Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.
Advertisement

Related Content

The Triumph of Part D
Not So Random Selection: Medicare Agency Cuts "Churn" In Part D Enrollment
Paying for Protection: Medicare Rebates May Make Protected Classes Less Safe for Sponsors
Sticker Shock: The Debate Over Making Part D Pricing Data Public
Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices
Big Stakes for Big Pharma in the Push Towards Full Enrollment in Part D
Big Pharma's Secret Weapon: Medicare Starts to Pay Off-Quietly
CMS Takes Sides in the Statin Wars
Lilly Stands Firm Against Florida Price Negotiations
Lipitor II

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel